Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421611 | 1.00 | TSHR (0.41) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22589228 | 0.78 | HPGD (0.34) | ALDH1A1SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL22589227 | 0.78 | HPGD (0.34) | ALDH1A1SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL17146906 | 0.77 | TSHR (0.59) | TSHRALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12279519 | 0.73 | CSNK1D (0.45) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31082872 | 0.73 | TSHR (0.41) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28882232 | 0.73 | CSNK1D (0.45) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26659825 | 0.72 | CYP2C9 (0.43) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29421500 | 0.72 | TSHR (0.53) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL352645 | 0.72 | TSHR (0.53) | TSHRALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | TSHR 4567/4885ALDH1A1 1225/4885MEN1 2928/4885 |
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885MEN1 823/4885 |
| US-20240150328-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885MEN1 823/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | TSHR 4655/4885ALDH1A1 2034/4885MEN1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.